Dernières nouvelles pour Chemed (NYSE:CHE) Stock

CHEMED CORP

Chemed

Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. Through its subsidiaries, the company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham analyst Ryan Koontz initiated coverage on Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) with a Buy rating and announced a price target of $32. Applied Optoelectronics shares closed at $25.84 on Thursday. <a href="https://www.benzinga.com/quote/aaoi/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Richard Law initiated coverage on Arcutis Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) with a Neutral rating and announced a price target of $18. Arcutis Biotherapeutics shares closed at $15.02 on Thursday. <a href="https://www.benzinga.com/quote/arqt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho analyst Steven Valiquette initiated coverage on Teladoc Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Neutral rating and announced a price target of $10. Teladoc Health shares closed at $8.20 on Thursday. <a href="https://www.benzinga.com/quote/tdoc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Brent Bracelin initiated coverage on Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) with an Overweight rating and announced a price target of $170. Palantir Technologies shares closed at $154.86 on Thursday. <a href="https://www.benzinga.com/quote/pltr/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Brian Tanquilut initiated coverage on Chemed Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) with a Hold rating and announced a price target of $500. Chemed shares closed at $463.02 on Thursday. <a href="https://www.benzinga.com/quote/che/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PLTR stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/PLTR/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="598" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25083242/image-399-1024x598.png" alt="" class="wp-image-1000712" style="width:627px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25083242/image-399-1024x598.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25083242/image-399-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25083242/image-399-768x448.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25083242/image-399.png 1141w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46599936/top-2-tech-stocks-you-may-want-to-dump-this-quarter">Top 2 Tech Stocks You May Want To Dump This Quarter</a></li>
</ul>
Photo via Shutterstock

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

AAOI

ARQT

PLTR

TDOC

This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Jefferies analyst Brian Tanquilut initiates coverage on Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) with a Hold rating and announces Price Target of $500.

Price Target

Jefferies Initiates Coverage On Chemed with Hold Rating, Announces Price Target of $500

Chemed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) short percent of float has fallen 14.96% since its last report. The company recently reported that it has 431 thousand shares sold short, which is 3.41% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.83 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Chemed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752850867_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Chemed has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Chemed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Chemed's peer group average for short interest as a percentage of float is 10.43%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Chemed's Recent Short Interest

In the current market session, Chemed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) price is at $454.81, after a 0.24% spike. However, over the past month, the stock fell by 16.85%, and in the past year, by 16.24%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1752685237_0.png" alt="Past Year Chart" />

<h3>Evaluating Chemed P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Chemed has a lower P/E than the aggregate P/E of 40.99 of the Health Care Providers &amp; Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1752685237_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Price Over Earnings Overview: Chemed

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 10 years by 1.47% on an annualized basis producing an average annual return of 12.85%. Currently, Chemed has a market capitalization of $6.64 billion. 
Buying $1000 In CHE: If an investor had bought $1000 of CHE stock 10 years ago, it would be worth $3,363.88 today based on a price of $453.72 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752619513_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 10 years by 1.79% on an annualized basis producing an average annual return of 13.26%. Currently, Chemed has a market capitalization of $6.90 billion. 
Buying $1000 In CHE: If an investor had bought $1000 of CHE stock 10 years ago, it would be worth $3,495.96 today based on a price of $471.57 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752097512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Chemed Stock In The Last 10 Years

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 0.3% on Monday.
The Dow traded up 0.45% to 44,014.63 while the NASDAQ gained 0.32% to 20,338.93. The S&amp;P 500 also rose, gaining, 0.33% to 6,193.57.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46168293/top-2-consumer-stocks-that-are-ticking-portfolio-bombs">Top 2 Consumer Stocks That Are Ticking Portfolio Bombs</a>
Leading and Lagging Sectors Financials shares jumped by 0.8% on Monday.
In trading on Monday, consumer discretionary stocks fell by 0.8%.
Top Headline
Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) and Juniper Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>) reached an agreement with the U.S. Department of Justice (DOJ) on Saturday.
This settlement, subject to court approval, resolves the DOJ's lawsuit that challenged HPE's acquisition of Juniper and paves the way for the transaction to close.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Bitmine Immersion Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NASDAQ">BMNR</a>) shares shot up 442% to $23.10 after the company announced a $250 million private placement to launch an Ethereum treasury strategy.</li>
<li>Shares of Artelo Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) got a boost, surging 102% to $13.70 after the company announced data from its first-in-human study for ART26.12.</li>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) shares were also up, gaining 15% to $10.81 after the company announced it completed a series of test flights in Dubai.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Fortive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) shares dropped 5% to $51.03 as the company announced the completion of the Ralliant separation and appointment of Olumide Soroye as President, CEO and Director of Fortive.</li>
<li>Shares of INmune Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) were down 59% to $2.1680 after the company announced its Phase 2 MINDFuL trial did not meet its primary cognitive endpoint.</li>
<li>Chemed Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) was down, falling 15% to $475.29 after B of A Securities cut its price target on the stock from $708 to $650.</li>
</ul>
Commodities In commodity news, oil traded down 0.8% to $65.03 while gold traded up 0.5% at $3,304.40.
Silver traded down 0.5% to $36.20 on Monday, while copper fell 0.8% to $5.0820.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.42%, while Spain's IBEX 35 Index gained 0.16%. London's FTSE 100 fell 0.43%, Germany's DAX 40 declined 0.51% and France's CAC 40 slipped 0.33% during the session.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei gaining 0.84%, Hong Kong's Hang Seng Index falling 0.87%, China's Shanghai Composite gaining 0.59% and India's BSE Sensex falling 0.54%.
Economics
<ul class="wp-block-list">
<li>The Chicago PMI fell to 40.4 for June from 40.5 in May, and compared to market estimates of 42.7.</li>
<li>The Dallas Fed's general business activity index for Texas manufacturing climbed to a reading of -12.7 in June compared to -15.3 in the previous month.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/46168575/wall-streets-most-accurate-analysts-spotlight-on-3-defensive-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Defensive Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

ARTL

BMNR

INMB

JNPR

JOBY

Crude Oil Moves Lower; Joby Aviation Shares Surge

RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) with a Outperform and lowers the price target from $674 to $640.

RBC Capital Maintains Outperform on Chemed, Lowers Price Target to $640

WIIM

Chemed shares are trading lower after B of A Securities cut its price target on the stock from $708 to $650.

B of A Securities analyst Joanna Gajuk maintains Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) with a Buy and lowers the price target from $708 to $650.

B of A Securities Maintains Buy on Chemed, Lowers Price Target to $650

Chemed To Report Second-Quarter 2025 Earnings July 29, 2025
Provides Current Update to 2025 Earnings Performance
Related Conference Call to Be Held On July 30, 2025
﻿
CINCINNATI, June 27, 2025--Chemed Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) today announced that it will release financial results for the second quarter ended June 30, 2025, on Tuesday, July 29, 2025, following the close of trading on the New York Stock Exchange.
﻿
Chemed also announced developments related to second quarter earnings and full year 2025 guidance.
﻿
In prior public statements, management discussed the possibility that the VITAS subsidiary could have an aggregate Medicare Cap billing limitation (Medicare Cap) related to its Florida consolidated program, excluding Tallahassee. However, as of the most recent quarterly earnings update, VITAS internal projections showed that the Florida consolidated program would end the 2025 government fiscal year ending on September 30, 2025 (2025 Cap Year) with a Medicare Cap cushion. Actual Medicare admissions in both April and May 2025 in Florida were weaker than anticipated and lower than VITAS' internal projections. As a result, VITAS now projects a Medicare Cap revenue limitation for the 2025 Cap Year of $18 million to $25 million related to the Florida consolidated program, excluding Tallahassee. The above projection includes actual results through May. Actual June results, which show better admissions than projected through the first half of the month, and actual results in the third quarter could have a significant impact on this projection. Previous guidance for 2025 earnings did not include any Florida Medicare Cap.
﻿
The source of the Medicare Cap in the Florida consolidated program relates to two factors. The first factor is the "community access" program. While community access has provided for a higher-than-average ADC growth rate and revenue growth rate at VITAS over the past two years, it adds pressure to the Medicare Cap due to patients accessing hospice care earlier in their disease trajectory.
﻿
The second factor is the rate differential between the nationally determined increase in the Medicare Cap per admission and the actual reimbursement increase in our Florida consolidated programs, excluding Tallahassee, for the 2025 Cap Year. Specifically, the Medicare Cap per admission amount increased 2.9% while the Florida consolidated program reimbursement increase was 5.2%. VITAS estimates this rate differential will negatively impact the Florida consolidated program's Medicare Cap calculation by approximately $25 million for the 2025 government fiscal year, accounting for most, if not all, of the total revenue limitation discussed above.
﻿
&nbsp;
&nbsp;
On June 20, 2025, the State of Florida announced that VITAS has received a Certificate of Need (CON) to begin operating in Pinellas County, Florida. Pinellas is the most densely populated county in Florida and has a hospice utilization rate below the state average. There were approximately 8,600 Medicare admissions to existing hospice providers in Pinellas County in 2024. Entering Pinellas County represents a significant opportunity for VITAS in 2026 and beyond for both overall growth and Medicare Cap mitigation.
﻿
Based on the new start locations in Florida, primarily Marion County and Pinellas County, combined with operational changes currently being made in the Florida programs, management expects not to have any significant level of Medicare Cap revenue limitation in our Florida consolidated program for the 2026 fiscal year. This expectation assumes that the rate differential discussed above does not recur for the 2026 Cap Year.&nbsp;&nbsp;In the event that the rate differential does recur, VITAS will respond with further mitigation strategies at the outset of the 2026 Cap Year.
﻿
While less financially significant than the VITAS Medicare Cap situation, during the second quarter of 2025, Roto-Rooter began to experience unexpected weakness in its residential business' demand compared to internal projections. This weakness represents a break from the trends experienced in the first quarter of 2025. Preliminary results for commercial demand in the second quarter of 2025 continue to reflect improved trends but not enough to offset the lower residential demand.
﻿
Management is in the process of analyzing second quarter performance and the impact of these developments on second quarter results and on full-year 2025 guidance. A full discussion of the analysis will be included with our second quarter 2025 release and related investor conference call.
﻿
Chemed will host a conference call and webcast at 10 a.m., ET, on Wednesday, July 30, 2025, to discuss the company's quarterly results and to provide an update on its business.
Participants may access a live webcast of the conference call through the investor relations section of Chemed's website, Investor Relations Home &#x7C; Chemed Corporation or the hosting website <a href="https://edge.media-server.com/mmc/p/vzh53v7p" title="https://edge.media-server.com/mmc/p/vzh53v7p">https://edge.media-server.com/mmc/p/vzh53v7p</a>.
Participants may also register via teleconference at: https://register-conf.media-server.com/register/BI1cf6ed1d293547f9af3111729ba98b48.
Once registration is completed, participants will be provided with a dial-in number containing a personalized conference code to access the call. All participants are instructed to dial-in 15 minutes prior to the start time.
﻿
A taped replay of the conference call will be available beginning approximately two hours after the call's conclusion. You may access the replay via webcast through the investor relations section of Chemed's website.
﻿
Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (<a href="http://www.chemed.com/">www.chemed.com</a>) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation's leading provider of plumbing and drain cleaning services.

Guidance

Chemed Projects $18M–$25M Medicare Cap Revenue Limitation For VITAS Florida Program In 2025 Due To Weaker Admissions And Rate Disparity; Says Management Is In The Process Of Analyzing Q2 Performance And The Impact Of These Developments On Q2 Results And On FY25 Guidance; Expects No Significant Medicare Cap Impact In 2026

Chemed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) short percent of float has risen 23.16% since its last report. The company recently reported that it has 422 thousand shares sold short, which is 3.35% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.61 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Chemed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750442433_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Chemed has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Chemed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Chemed's peer group average for short interest as a percentage of float is 9.28%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is the Market Bullish or Bearish on Chemed?

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 10 years by 4.45% on an annualized basis producing an average annual return of 15.36%. Currently, Chemed has a market capitalization of $8.04 billion. 
Buying $1000 In CHE: If an investor had bought $1000 of CHE stock 10 years ago, it would be worth $4,174.45 today based on a price of $549.65 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750201214_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Chemed 10 Years Ago Would Be Worth Today

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 15 years by 4.84% on an annualized basis producing an average annual return of 16.72%. Currently, Chemed has a market capitalization of $8.33 billion. 
Buying $100 In CHE: If an investor had bought $100 of CHE stock 15 years ago, it would be worth $1,017.09 today based on a price of $569.57 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748275213_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Chemed 15 Years Ago Would Be Worth Today

Chemed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) short percent of float has fallen 3.17% since its last report. The company recently reported that it has 231 thousand shares sold short, which is 1.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.62 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Chemed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747832435_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Chemed has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Chemed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Chemed's peer group average for short interest as a percentage of float is 9.60%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

In the current market session, Chemed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) price is at $571.49, after a 2.57% spike. However, over the past month, the stock fell by 4.54%, and in the past year, by 2.35%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1747238428_0.png" alt="Past Year Chart" />

<h3>Chemed P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 55.75 in the Health Care Providers &amp; Services industry, Chemed Inc. has a lower P/E ratio of 27.17. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747238428_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

P/E Ratio Insights for Chemed

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 10 years by 5.49% on an annualized basis producing an average annual return of 16.17%. Currently, Chemed has a market capitalization of $8.36 billion. 
Buying $1000 In CHE: If an investor had bought $1000 of CHE stock 10 years ago, it would be worth $4,535.11 today based on a price of $571.49 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747233913_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 20 years by 6.22% on an annualized basis producing an average annual return of 14.22%. Currently, Chemed has a market capitalization of $8.40 billion. 
Buying $100 In CHE: If an investor had bought $100 of CHE stock 20 years ago, it would be worth $1,473.55 today based on a price of $574.50 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746027013_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Chemed Stock In The Last 20 Years

RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) with a Outperform and raises the price target from $667 to $674.

RBC Capital Maintains Outperform on Chemed, Raises Price Target to $674

Chemed shares are trading lower. The company reported Q1 financial results.

Press Releases

Chemed To Report Fourth-Quarter 2024 Earnings February 26, Related Conference Call To Be Held On February 27

Chemed Corporation Declares Quarterly Dividend of 50 Cents

Chemed Reports Fourth-Quarter 2024 Results

Chemed Corporation to Present at the Oppenheimer 35th Annual Healthcare Conference

Chemed To Report First-Quarter 2025 Earnings April 23, Related Conference Call To Be Held On April 24

Chemed Reports First-Quarter 2025 Results

Chemed Corporation to Present at the Bank of America Securities Health Care Conference 2025

Chemed Corporation to Present at the 2025 RBC Global Healthcare Conference

Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend

Chemed To Report Second-Quarter 2025 Earnings July 29, 2025

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Chemed

Actualités

Dernières nouvelles pour Chemed (NYSE:CHE) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL